564 results about "Atopic dermatitis" patented technology

To provide a pharmaceutical agent that has STAT6 inhibitory activity and is effective for the treatment of allergic diseases and inflammatory diseases such as atopic dermatitis.SOLUTION: A pharmaceutical agent contains, as an active ingredient, a compound represented by the general formula (I) in the figure or a pharmaceutically acceptable salt thereof, which has STAT6 inhibitory activity.SELECTED DRAWING: None

The invention relates to a novel application of animal bifidobacterium subsp. Lactis BGI-N3, in particular to an application of the animal bifidobacterium subsp. Lactis BGI-N3 in preparation of a preparation for relieving skin allergy. The invention finds that the bifidobacterium animalis subsp. Lactis BGI-N3 has a very remarkable effect in the aspect of relieving skin allergy, and the effect is specifically shown as follows: in an atopic dermatitis animal model, the dermatitis score, scratching times and percutaneous water loss are remarkably reduced, and the atopic dermatitis skin tissue damage condition is relieved; the immune organ edema condition is improved, the levels of Th2 type cell factors and inflammatory factors IL-6, TNF-alpha and IFN-gamma related to dermatitis are reduced, and the immune balance of the body is recovered; expression of fibroin and endothelial protein in skin tissue is improved, and the skin barrier is repaired; the level of antibacterial peptide in skin tissues is recovered, and the antibacterial activity of the skin is enhanced. Meanwhile, compared with a traditional chemical medicine for treating atopic dermatitis, the animal bifidobacterium subsp. Lactis BGI-N3 has no side effects such as weight loss, immune organ atrophy, immune imbalance and the like.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The invention relates to the technical field of biological medicine, and particularly discloses an atopic dermatitis treatment medicine and a preparation method and application thereof.The preparation method comprises the steps that sodium alginate, sodium polyacrylate and water are mixed and then subjected to a swelling reaction, and a colloidal solution with the viscosity larger than or equal to 5000 cP is formed; mixing upatinib, a preservative, glycerol and azone to obtain a raw material phase; and mixing the colloidal solution with the raw materials, and homogenizing to obtain the atopic dermatitis treatment medicine. Through swelling reaction of sodium alginate and sodium polyacrylate, the viscosity of a colloidal solution is remarkably improved through molecular chain entanglement, charge repulsion and water absorption synergistic effects of sodium alginate and sodium polyacrylate; through compounding of all the components, the transdermal efficiency of the medicine is improved, the irritation of the medicine is reduced, and meanwhile, the inhibition efficiency on atopic dermatitis inflammatory factors is also improved.

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

The invention discloses application of a zingiber mioga extract in preparation of a medicine for treating atopic dermatitis, and belongs to the technical field of medicines.The zingiber mioga extract is specifically a zingiber mioga rhizome aqueous extract, can act on all stages of atopic dermatitis to achieve the purposes of relieving inflammation and improving itching symptoms, has higher safety and effectiveness, and can be used for preparing a medicine for treating atopic dermatitis. Therefore, the traditional Chinese medicine composition has great potential and unique advantages in the aspect of treating atopic dermatitis. The invention provides a new thought for developing the atopic dermatitis medicine, and also expands the application direction of the zingiber mioga.

The invention belongs to the technical field of new application of medicines, and particularly relates to application of ganoderan GLP-2 in preparation of a medicine for improving atopic dermatitis. The structural formula of the ganoderma lucidum polysaccharide GLP-2 is as follows: # imgabs0 #, wherein m is equal to 10; n = 7. The research on the action mechanism of the ganoderan on mice with atopic dermatitis is discussed, theoretical guidance and practical experience are provided for further research of the ganoderan and products thereof, and the method has important theoretical value and application value.

The present invention relates to anti-canine IL-4Rα monoclonal antibodies of high potency regarding inhibition of IL-4Rα signaling pathway, and the use thereof for treating and / or preventing itch and / or inflammatory skin due to atopic dermatitis and allergies in dogs, and in particular for treating canine atopic dermatitis.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The present invention relates to a composition for treating atopic dermatitis, the composition comprising stichopus japonicus-derived extracellular vesicles. Treating LPS-induced inflammation macrophages and mouse models with stichopus japonicus-derived extracellular vesicles was found to activate anti-inflammatory effects. Accordingly, the composition comprising stichopus japonicus-derived extracellular vesicles has an excellent therapeutic effect on atopic dermatitis and can be utilized in the field of researching better therapeutic effects, and thus can be used in useful businesses related to atopic dermatitis.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker.　More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.

The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating atopic dermatitis. The traditional Chinese medicine composition contains cynanchum paniculatum, tripterygium wilfordii, bletilla striata, cuttlebone, duckweed, mint, radix sophorae flavescentis, golden cypress, moutan bark and liquorice. In addition, the invention further provides a traditional Chinese medicine preparation for treating atopic dermatitis and a preparation method and application of the traditional Chinese medicine preparation. The traditional Chinese medicine composition has the effects of dispelling wind, relieving itching, astringing to stop bleeding, clearing heat, drying dampness, detoxifying and dredging collaterals, and has no toxic or side effect.

The invention discloses an extracellular vesicle derived from rhodomonas mucilaginosa and a hydrogel composition of the extracellular vesicle. The extracellular vesicle is obtained by carrying out ultrafiltration concentration and gradient ultracentrifugation on a culture bacterium solution. Compared with an original culture solution or a viable bacterium preparation thereof, the treatment efficiency and the safety of the extracellular vesicles are remarkably improved. Based on the extracellular vesicle, the invention also provides a hydrogel composition loaded with the extracellular vesicle, and the hydrogel composition is constructed from the extracellular vesicle, type I collagen, carboxymethyl chitosan and four-arm polyethylene glycol benzaldehyde in a chemical crosslinking manner, and has good adhesiveness, self-repairing ability and injectability. The extracellular vesicle, the hydrogel composition and the hydrogel preparation of the extracellular vesicle can serve as a medicine or a medicine carrier to be applied to atopic dermatitis, can specifically target 2-type inflammatory factors, and relieve pathological changes such as skin lesion phenotype, epidermis thickening, mast cell infiltration and inflammatory factor expression increase of an MC903-induced atopic dermatitis mouse model.

The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).

The invention discloses an application of glucopyranose sulfate galactooligosacharide in preparation of a medicine for treating atopic dermatitis. The glucopyranose galactooligosaccharide can significantly improve the skin condition of a DNCB-induced atopic dermatitis mouse model, including reducing the skin inflammatory factor level, improving the skin barrier function, and reducing the lymph node quality and the number of lymphocytes, and has no abnormal influence on blood routine. The composition has the advantages of small drug application dosage, low pharmaceutical cost, safety, no side effect, strong drug effect and the like, and has a wide application prospect.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The present application relates to an NEK7 inhibitor, a pharmaceutical composition and a use thereof. The compound has a structural formula of formula (I). The compound of the present disclosure has good NEK7 inhibitory activity, and can be used for treating or preventing inflammatory pathological disorders (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout, etc.) regulated by the NLRP3 inflammasome.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention discloses a hydrogel dressing for treating atopic dermatitis and a preparation method and application thereof, and belongs to the technical field of skin medical materials. The dressing is prepared by taking a glycerol / water / ethanol ternary mixed solvent as a dissolving system, dissolving polyvinyl alcohol, tannic acid and aluminum trichloride to construct a polymer skeleton matrix, and then adding traditional Chinese medicine active ingredients. The preparation does not need complex temperature control curing, the ternary solvent can realize uniform dissolution and stable dispersion of the active ingredients, the effective ingredients are prevented from being damaged by high temperature, the encapsulation efficiency of the traditional Chinese medicine extract is more than 90%, and the medicine can be slowly released for 72 hours. The dressing has a multi-target anti-inflammatory effect, can reduce the level of TNF-alpha at a skin lesion and promote proliferation of keratinocytes, is excellent in tensile and torsional stability, and can be attached to the skin for a long time in a dynamic environment. The preparation method is simple in process, controllable in raw material cost, high in production efficiency, suitable for large-scale production, good in dressing biocompatibility, high in safety, suitable for treatment of atopic dermatitis of different severity degrees and large in clinical transformation potential.

Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.

The invention discloses a medicine composition for treating atopic dermatitis, a preparation method and application, the medicine composition comprises inactivated malassezia sphaeroides, and the strain preservation number of the malassezia sphaeroides is ATCC 96807. The cream composition disclosed by the invention is externally applied to local treatment of skin lesions of specific dermatitis, supplements skin symbiotic bacteria, assists in recovering skin barriers of patients, remarkably inhibits growth and proliferation of staphylococcus aureus at the skin lesions of dermatitis and exocrine toxins, remarkably relieves inflammatory response, reduces the thickness of cuticles and reduces inflammatory cell infiltration; the traditional Chinese medicine composition assists the treatment of atopic dermatitis through the effects of the proinflammatory factors and the expression and secretion of the proinflammatory factors, has a remarkable treatment effect on the atopic dermatitis, is quick to take effect, small in toxic and side effects and good in safety, and has a good medicinal prospect.

A use of liquiritin in the preparation of a drug for treating atopic dermatitis. Animal experiments show that liquiritin can remarkably lessen the skin lesion severity of an atopic dermatitis mouse model, reduce the ear thickness and the epidermal thickness, and reduce the infiltration degree of dermal lymphocytes, thereby demonstrating that liquiritin has a significant therapeutic effect on atopic dermatitis, has no toxic and side effects on the liver, the spleen and the kidney, and has good clinical application prospects and enormous social benefits, and expanding a new application field for a conventional leguminous plant liquorice extract, i.e., liquiritin.

Disclosed are an antibody targeting IL-31RA or an antigen-binding fragment thereof and a use thereof. The antibody or the antigen-binding fragment thereof provided by the present invention can specifically bind to IL-31RA, and competitively inhibit the downstream signal pathway mediated by cytokine IL-31, effectively reducing the inflammatory response; and a pharmaceutical composition containing an anti-IL-31RA antibody can be used for treating or preventing atopic dermatitis, pruritus, prurigo nodularis, or systemic sclerosis.

The invention belongs to the technical field of microorganisms, and discloses a bifidobacterium animalis subsp. Lactis XB02 strain capable of inhibiting pathogenic bacteria and improving inflammation, the preservation number of the bifidobacterium animalis subsp. Lactis XB02 strain is CGMCC (China General Microbiological Culture Collection Center) No.34942, and the preservation date is June 18, 2025. Meanwhile, the probiotic composition adopting the bacterial strain XB02 also comprises a lactobacillus rhamnosus XB01 bacterial strain. The XB02 strain disclosed by the invention has excellent bacteriostatic activity, especially for vibrio parahaemolyticus and gardneria; the atopic dermatitis symptom can be obviously improved; the intestinal mucosa permeability is reduced, and the intestinal barrier function is enhanced; and when the strain is combined with the XB01 strain for use, a synergistic sleep promoting effect is shown. The invention further provides a probiotic composition containing the strain, a preparation and application of the probiotic composition and the preparation in food, medicine or health care products.

The present invention relates to a composition comprising a mixture of exosomes derived from different cells, as an active ingredient and use thereof. More specifically, the present invention relates to a composition for treating skin diseases and / or improving skin conditions, comprising, as an active ingredient, mixed exosomes or fused exosomes in which natural killer cell-derived exosomes and mesenchymal stem cell-derived exosomes are mixed or fused. The composition according to the present invention exhibits an excellent cell proliferation effect and the effect of promoting collagen production, and thus can be effectively used as not only a cosmetic material for improving skin conditions, such as by reducing skin wrinkles, regenerating wounds, and increasing elasticity, but also a pharmaceutical material for preventing or treating skin diseases such as atopic dermatitis.

The invention discloses application of METTL1 as a target spot in preparation of a medicine for treating erythema squamous skin diseases, relates to the field of biological medicines, provides a new scheme for treatment of erythema squamous skin diseases, especially psoriasis and atopic dermatitis, relieves inflammatory response of psoriasis or atopic dermatitis by inhibiting expression of METTL1, and provides a new application of METTL1 as a target spot in preparation of medicines for treating erythema squamous skin diseases, especially psoriasis and atopic dermatitis. And erythema, scales and skin thickness are reduced.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention relates to a construction method of an atopic dermatitis mouse model. The method sequentially comprises the following steps: screening mice, feeding the mice in an SPF (specific pathogen free)-level animal house by adopting an illumination and darkness alternating period, and freely taking standard feed and drinking water; after the animals adapt to the environment, the animals are divided into a model group and a control group, and the control group is only subjected to first sensitization treatment; the model group is subjected to first-time sensitization treatment and maintenance treatment, the interval between the first-time sensitization treatment and the maintenance treatment is 4 days, and the maintenance treatment is performed for three times per week and is totally 16 days continuously. According to the method disclosed by the invention, the mouse model which is highly similar to human atopic dermatitis in immunology, pathology and molecular level is successfully established, the limitations of poor repeatability, incomplete pathological characteristics, single immunoreaction type and the like of the existing model are overcome, and an effective experimental platform is provided for disease research and new drug development.